PD Dr. Frank Breitenbücher

Research interests: 
  • Molecular pathognese of lung cancer
  • Drug discovery in cancer treatment
CoLab Biomed research keywords: 
Selected publications: 

Hoffmann G, Breitenbücher F, Schuler M, Ehrenhofer-Murray AE. A Novel Sirtuin 2 (SIRT2) Inhibitor with p53-dependent Pro-apoptotic Activity in Non-small Cell Lung Cancer. J Biol Chem. 2014 Feb 21;289(8):5208-16.

Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler TC, Köhler J, Herold T, Kurt Werner S, Freitag L, Kasper S, Schuler M. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS One. 2014 Jan 21;9(1):e85350.

Wiesweg M, Ting S, Reis H, Worm K, Kasper S, Tewes M, Welt A, Richly H, Meiler J, Bauer S, Hense J, Gauler TC, Köhler J, Eberhardt WE, Darwiche K, Freitag L, Stamatis G, Breitenbücher F, Wohlschlaeger J, Theegarten D, Derks C, Cortes-Incio D, Linden G, Skottky S, Lütkes P, Dechêne A, Paul A, Markus P, Schmid KW, Schuler M. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. Eur J Cancer. 2013 Oct;49(15):3076-82.

Molzan M, Kasper S, Röglin L, Skwarczynska M, Sassa T, Inoue T, Breitenbuecher F, Ohkanda J, Kato N, Schuler M, Ottmann C. Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers. ACS Chem Biol. 2013 Sep 20;8(9):1869-75.

Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T, Taeger G, Eilers G, Treckmann J, Breitenbuecher F, Schuler M, Taguchi T, Fletcher JA, Bauer S. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res. 2013 Jun 15;73(12):3661-70.

Meiler J, Guyot M, Hoffarth S, Wesarg E, Höhn Y, Breitenbuecher F, Schuler M. Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2012 Aug;138(8):1385-94.

Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C, Fischer T. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood. 2009 Apr 23;113(17):4074-7.

Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Böhmer FD, Masson K, Rönnstrand L, Huber C, Kindler T, Fischer T. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood. 2009 Apr 23;113(17):4063-73.

Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, Groner S, Späth D, Krauter J, Ganser A, Döhner H, Fischer T, Döhner K; German-Austrian AML Study Group (AMLSG). Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009 Sep 17;114(12):2386-92.

Becker S, Markova B, Wiewrodt R, Hoffarth S, Hähnel PS, Pleiner S, Schmidt LH, Breitenbuecher F, Schuler M. Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. J Thorac Oncol. 2011 Dec;6(12):1976-83.

Markova B, Hähnel PS, Kasper S, Herbertz S, Schuler M, Breitenbuecher F. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. J Cancer Res Clin Oncol. 2012 Apr;138(4):545-54.

Research group: 
Medical Faculty
West German Cancer Center (WTZ)
University Hospital Essen
Contact information: 

Phone:
+49 201 723 1630

Adress:
Universitätsklinikum Essen
Hufelandstraße 55
45147 Essen